US · TEM
Tempus AI, Inc.
- Sector
- Healthcare · Medical - Healthcare Information Services
- Headquarters
- Chicago, IL 60654
- Website
- tempus.com
Price · as of 2025-12-31
$55.00
Market cap 9.2B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $54.65 | -0.64% |
| Intrinsic Value(DCF) | $12,848.08 | +23,260.15% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $0.00 | $0.00 | |||
| 2021 | $0.00 | $0.00 | |||
| 2022 | $0.00 | $0.00 | |||
| 2023 | $0.00 | $0.00 | |||
| 2024 | $49.10 | $39.08 | $156.15 | $0.00 | $0.00 |
| 2025 | $53.31 | $54.65 | $14,207.09 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Tempus AI, Inc.'s (TEM) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $54.65
- Current price
- $55.00
- AI upside
- -0.64%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$12,848.08
+23,260.15% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TEM | Tempus AI, Inc. | $55.00 | 9.2B | -1% | +23,260% | — | — | -37.91 | 18.91 | 7.30 | -42.05 | — | -27.80 | 69.64% | -18.76% | -19.27% | -89.48% | -62.74% | -15.31% | 1.66 | -3.40 | 3.13 | 2.86 | -0.95 | -6937.00% | 8341.00% | 1325.00% | -2.57% | -0.59 | -76.13% | 0.00% | 0.00% | 0.03% | -39.18 | -39.10 | 7.35 | 3.76 |
| CNC | Centene Corporation | $44.88 | 22.07B | -25% | +2,787% | — | — | -3.28 | 1.10 | 0.11 | -4.43 | — | 4.77 | 12.24% | -3.91% | -3.43% | -28.80% | -30.25% | -8.34% | 0.94 | -11.24 | 1.68 | 1.68 | -0.17 | -31585.00% | 1944.00% | -98184.00% | 19.73% | 0.24 | 17.29% | 0.00% | 0.00% | 22.61% | -2.99 | 5.27 | 0.12 | 2.79 |
| COO | The Cooper Companies, Inc… | $83.67 | 16.63B | -16% | -60% | -63% | -71% | 44.52 | 2.03 | 4.08 | 18.38 | — | 5.96 | 60.67% | 16.69% | 9.16% | 4.59% | 4.21% | 3.03% | 0.34 | 6.83 | 1.89 | 0.84 | 2.54 | -459.00% | 506.00% | 5054.00% | 2.60% | 0.72 | 4.04% | 0.00% | 0.00% | 1.74% | 28.35 | 44.65 | 4.73 | 3.88 |
| DOCS | Doximity, Inc. | $24.53 | 4.61B | +213% | +46% | -54% | +33% | 49.27 | 10.16 | 19.28 | 41.92 | 90.95 | 11.09 | 90.20% | 39.94% | 39.13% | 22.50% | 116.06% | 19.05% | 0.01 | — | 6.97 | 6.68 | -0.82 | 5417.00% | 1998.00% | 4961.00% | 2.43% | 1.75 | 160.49% | 0.00% | 0.00% | 2.14% | 44.30 | 37.84 | 17.69 | 38.45 |
| FMS | Fresenius Medical Care AG… | $23.46 | 13.52B | -1% | -60% | +12% | -19% | 11.94 | 0.82 | 0.60 | 7.06 | 14.46 | -21.51 | 25.62% | 9.31% | 4.98% | 6.78% | 6.03% | 3.03% | 0.76 | — | 1.26 | 0.76 | 3.11 | 8261.00% | 151.00% | 54.00% | 14.52% | 0.41 | 7.11% | 3.47% | 41.50% | 13.67% | 11.43 | 12.31 | 1.06 | 1.31 |
| HOLX | Hologic, Inc. | $75.36 | 16.82B | +9% | -53% | -75% | -67% | 30.11 | 3.37 | 4.15 | 17.05 | — | 20.82 | 61.00% | 17.42% | 13.80% | 11.12% | 10.86% | 6.23% | 0.52 | 16.73 | 3.75 | 2.87 | 0.65 | -2500.00% | 174.00% | -1964.00% | 5.40% | 1.08 | 16.84% | 0.00% | 0.00% | 4.42% | 24.44 | 18.97 | 4.26 | 4.18 |
| ICLR | ICON Public Limited Compa… | $108.14 | 8.26B | +89% | -31% | -50% | -11% | 19.44 | 1.62 | 1.86 | 11.80 | 67.55 | -4.98 | 29.42% | 13.26% | 9.56% | 8.44% | 7.88% | 4.67% | 0.38 | 4.63 | 1.26 | 1.21 | 1.96 | 2878.00% | 199.00% | 963.00% | 7.27% | 0.46 | 8.81% | 0.00% | 0.00% | 6.47% | 16.81 | 16.50 | 2.23 | 2.24 |
| MEDP | Medpace Holdings, Inc. | $451.76 | 12.82B | -29% | +273% | -84% | -6% | 29.25 | 28.75 | 5.22 | 22.70 | 139.42 | -55.74 | 30.06% | 21.14% | 17.83% | 70.23% | 171.74% | 22.13% | 0.55 | — | 0.74 | 0.67 | -0.43 | 2098.00% | 1997.00% | 1915.00% | 5.17% | 0.53 | 263.19% | 0.00% | 0.00% | 6.95% | 24.21 | 18.99 | 5.12 | 6.85 |
| NBIX | Neurocrine Biosciences, I… | $132.25 | 13.27B | +32% | +46% | -57% | +4% | 27.52 | 4.05 | 4.60 | 18.16 | 65.61 | 4.05 | 98.18% | 21.64% | 16.73% | 16.38% | 20.21% | 11.46% | 0.13 | — | 3.39 | 2.92 | -0.45 | 4195.00% | 2145.00% | 3437.00% | 5.68% | 1.05 | 36.02% | 0.00% | 0.00% | 5.22% | 19.56 | 16.17 | 4.23 | 7.39 |
| SNN | Smith & Nephew plc | $36.90 | 16.13B | +1% | -68% | — | -68% | 30.99 | 2.43 | 2.20 | 12.51 | — | 10.58 | 69.64% | 11.31% | 7.09% | 7.86% | 6.81% | 4.05% | 0.63 | 3.91 | 2.89 | 1.19 | 2.18 | -2167.00% | 470.00% | 23481.00% | 4.75% | 0.64 | 7.59% | 2.56% | 79.40% | 3.19% | 23.55 | 25.53 | 2.66 | 3.29 |
| UHS | Universal Health Services… | $206.10 | 13.12B | -29% | -58% | -24% | +99% | 8.68 | 1.80 | 0.76 | 6.73 | 23.26 | 3.99 | 11.48% | 11.48% | 8.57% | 21.68% | 12.66% | 10.08% | 0.76 | 12.68 | 1.05 | 0.85 | 1.95 | 3734.00% | 971.00% | -2440.00% | 6.47% | 0.58 | 7.04% | 0.39% | 3.40% | 7.77% | 9.27 | 21.78 | 1.07 | 3.24 |
About Tempus AI, Inc.
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
- CEO
- Eric Lefkofsky
- Employees
- 2.4K
- Beta
- 5.31
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($12,848.08 ÷ $55.00) − 1 = +23,260.15% (DCF, example).